Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Controlled Clinical Trial of Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy in Patients With Oral/Oropharyngeal Squamous Cell Carcinoma

NCT07812467 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT07812467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07812467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Controlled Clinical Trial of Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy in Patients With Oral/Oropharyngeal Squamous Cell Carcinoma
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
October 31, 2033
Enrollment
220 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oral squamous cell carcinoma (oscc), oropharyngeal squamous cell carcinoma (opscc)